Bio-Rad Laboratories Quarterly Cash Flow Statement
NYSE: BIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bio-Rad Laboratories free cash flow
In the quarter ended Jun 30, 2026, Bio-Rad Laboratories generated $98.7 million of operating cash flow and spent $32.0 million on capital expenditures. That left free cash flow of $66.7 million, a free-cash-flow margin of 10.2% of revenue. Free cash flow was down 5.8% from the prior year's $70.8 million.
Bio-Rad Laboratories returned $31.5 million to shareholders through share repurchases, equal to 47% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Rad Laboratories cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 371.40M | -527.10M | 720.00M | -341.90M | 317.80M | 64.00M | -715.80M | 653.20M | -2.17B | 383.90M | 349.70M | 106.30M |
| Net Income growth (YoY) | +16.87% | -923.59% | — | -152.34% | — | -83.33% | -304.69% | +514.49% | — | +456.38% | -57.75% | — |
| Stock-Based Compensation | 14.50M | 15.00M | 15.90M | 14.90M | 11.90M | 15.30M | 16.40M | 15.60M | 15.00M | 15.30M | 16.20M | 15.90M |
| Change in Working Capital | -25.40M | 900.00K | 55.50M | 17.80M | -4.10M | 19.30M | 15.10M | 7.80M | -26.80M | 28.60M | -4.80M | 20.00M |
| Operating Cash Flow | 98.70M | 108.10M | 164.90M | 120.90M | 116.50M | 129.90M | 124.20M | 163.60M | 97.60M | 69.80M | 81.00M | 97.71M |
| Capital Expenditures | -32.00M | -30.00M | -45.80M | -31.70M | -45.70M | -34.40M | -42.90M | -40.20M | -42.30M | -40.20M | -42.27M | -44.07M |
| Investing Cash Flow | -66.70M | -93.20M | -34.20M | -43.00M | -115.40M | 2.90M | -30.50M | -55.70M | -30.90M | -43.10M | 72.19M | -9.50M |
| Share Repurchases | -31.50M | -47.80M | 0 | -53.40M | -140.20M | -101.90M | 0 | -97.90M | -101.00M | -4.70M | -199.97M | -21.32M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Repaid | -200.00K | -100.00K | -200.00K | 0 | -200.00K | -100.00K | 0 | -100.00K | -100.00K | -200.00K | -151.00K | -118.00K |
| Financing Cash Flow | -27.60M | -44.00M | 3.30M | -52.50M | -136.30M | -97.70M | -26.20M | -96.00M | -96.60M | 0 | -200.57M | -26.60M |
| Net Change in Cash | 9.80M | -23.20M | 134.00M | 26.50M | -151.40M | 33.30M | 77.60M | 4.50M | -26.10M | 29.40M | -53.87M | 67.83M |
| Free Cash Flow | 66.70M | 78.10M | 119.10M | 89.20M | 70.80M | 95.50M | 81.30M | 123.40M | 55.30M | 29.60M | 38.74M | 53.64M |
This table shows 12 quarterly periods of Bio-Rad Laboratories's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BIO's reporting calendar. What is a cash flow statement?